Table 5.

Treatment effect on hs-CRP levels

Study	n	Treatment	Effect	Clinical setting	p value
Ridker, Hennekens, et al 1999	472	Pravastatin 40 mg	↓ 17.4%	Secondary prevention	0.007
		Placebo	↑ 4.2%
Kinlay et al 2003	2402	Atorvastatin 80 mg	↓ 83%	Unstable	<0.0001
		Placebo	↓ 74%
Ridker et al 2005	3745	Atorvastatin 80 mg	↓ 89%	Unstable	<0.001
		Pravastatin 40 mg	↓ 82%
Nissen et al 2005	502	Atorvastatin 80 mg	↓ 36%	Stable and unstable	<0.001
		Pravastatin 40 mg	↓ 3%
Bogaty 2004	35	Rofecoxib 25 mg	↓ 59%	Stable	0.03
		Placebo	↑ 35%
Monakier 2004	34	Rofecoxib 25 mg	↓ 98%	Unstable	<0.02
		Placebo	↑ 100%
Fliser 2004	199	Olmesartan 20 mg	↓ 15.1%	Hypertension	<0.05
Després et al 2005	1036	Rimonabant 20 mg	↓18%	Overweight	0.020
		Placebo	↓7.5%
Wannamethee et al 2002	3628	Physical activity	↓ 18%	Stable (elderly men)	0.0005
Mattusch et al 1999	14	Endurance training	↓ 31%	Healthy subjects	<0.05
Chrysohoou et al 2004	3042	Mediterranean diet	↓ 20%	Stable	0.015

Abbreviations: hs-CRP, high sensitivity C-reactive protein.